Bone management in hematologic stem cell transplant recipients

D. L. Kendler, J. J. Body, M. L. Brandi, R. Broady, J. Cannata-Andia, M. J. Cannata-Ortiz, A. El Maghraoui, G. Guglielmi, P. Hadji, D. D. Pierroz, T. J. de Villiers, R. Rizzoli, P. R. Ebeling, for the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease

Research output: Contribution to journalReview ArticleResearchpeer-review

36 Citations (Scopus)


Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for patients with some malignant and non-malignant hematological diseases. Advances in transplantation techniques and supportive care measures have substantially increased the number of long-term HSCT survivors. This has led to an increasing patient population suffering from the late effects of HSCT, of which, bone loss and its consequent fragility fractures lead to substantial morbidity. Altered bone health, with consequent fragility fractures, and chronic graft-versus-host disease (GVHD) are factors affecting long-term quality of life after HSCT. Hypogonadism, HSCT preparative regimens, nutritional factors, and glucocorticoids all contribute to accelerated bone loss and increased fracture risk. Management strategies should include bone mineral density examination, evaluation of clinical risk factors, and general dietary and physical activity measures. Evidence has accumulated permitting recommendations for more attentiveness to evaluation and monitoring of bone health, with appropriate application of osteoporosis pharmacotherapies to patients at increased risk of bone loss and fracture.

Original languageEnglish
Pages (from-to)2597-2610
Number of pages14
JournalOsteoporosis International
Issue number12
Publication statusPublished - 1 Dec 2018


  • Bone loss
  • Bone marrow
  • Bone mineral density
  • Fracture
  • Hematopoietic stem cell
  • Transplantation

Cite this